Table 5 Anticancer activity of the selected synthesized analogous
From: Design, synthesis and biological potentials of novel tetrahydroimidazo[1,2-a]pyrimidine derivatives
MCF-7 | µMolar drug concentrations | ||
|---|---|---|---|
LC50 | TGI | GI a50 | |
1 | >100 | >100 | 82.82 |
3 | >100 | >100 | 75.3 |
10 | NE | NE | NE |
13 | >100 | >100 | 54 |
15 | >100 | >100 | 97.9 |
18 | >100 | >100 | 66.8 |
20 | >100 | >100 | 80.08 |
22 | >100 | >100 | 94.5 |
23 | >100 | 73.05 | 34.78 |
MNP | >100 | >100 | >100 |
ADR | 18.01 | <0.1 | <0.1 |